REGINfo: GALAPAGOS - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$GALAPAGOS: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2021.11.22 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease - HTML (w)

2021.11.22 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos voltooit patiëntenrekrutering voor MANGROVE fase 2-studie met GLPG2737 bij polycystische nierziekte - HTML (w)

2021.11.15 | 16:45 | Permanent Information Releases / General Company News

puce Jyseleca®?(filgotinib) approved in the European Union for the treatment of ulcerative colitis - HTML (w)

2021.11.15 | 16:45 | Permanent Information Releases / General Company News

puce Europese goedkeuring voor Jyseleca®?(filgotinib) voor de behandeling van colitis ulcerosa - HTML (w)

2021.11.04 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos rapporteert commerciële en operationele voortgang bij derde kwartaalresultaten - HTML (w)

2021.11.04 | 22:01 | Periodic information / 3rd Quarter Information

puce Galapagos reports commercial and operational progress at Q3 financial results - HTML (w)

2021.10.04 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress - HTML (w)

2021.10.04 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos presenteert nieuwe data van het SELECTION fase 3-programma op het 2021 congres van de United European Gastroenterology Week (UEGW) - HTML (w)

2021.10.04 | 07:01 | Permanent Information Releases / General Company News

puce Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease - HTML (w)

2021.10.04 | 07:01 | Permanent Information Releases / General Company News

puce Galapagos kondigt voltooiing aan van rekrutering voor DIVERSITY fase 3-studie met filgotinib bij patiënten met de ziekte van Crohn - HTML (w)

2021.09.20 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos increases share capital through subscription right exercises - HTML (w)

2021.09.20 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten - HTML (w)

2021.09.17 | 13:15 | Permanent Information Releases / General Company News

puce GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS - HTML (w)

2021.09.17 | 13:15 | Permanent Information Releases / General Company News

puce GALAPAGOS KONDIGT POSITIEVE CHMP OPINIE AAN VOOR JYSELECA® (FILGOTINIB) VOOR DE BEHANDELING VAN VOLWASSENEN MET MATIGE TOT ERNSTIGE ACTIEVE COLITIS ULCEROSA - HTML (w)

2021.08.30 | 22:01 | Permanent Information Releases / Appointments

puce Galapagos announces planned retirement of CEO - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 358